LONDON, May 9, 2012 /PRNewswire/ -- A monumental discovery that provides the promise of a cure not only for leukaemia, but cancer at large was announced this morning in London during GIL 2012: Europe. Steve Shor, the founder of the National Children's Leukemia Foundation, a leading non-profit organisation in the United States, unveiled a ground-breaking therapy his research teams in the United States and Israel have discovered. Mr. Shor and National Program Director, Dr. Sara Gardin, presented this new non-embryonic stem cell treatment for cancer and leukaemia, referred to as the "Stem cell cocktail" which delivers a combination of therapies including core stem cells and various compounds to tackle cell metastasization.
Just a few weeks ago, this unique approach to tackling one of the most prominent forms of cancer of our time received initial patent approval with full patents expected in the coming months.
Steve Shor delivered an emotional appeal and address that captured the undivided attention of some two hundred plus senior level business executives representing this global network of visionaries, innovators and leaders gathered in London for Frost & Sullivan's GIL 2012: Europe - Journey to Visionary Innovation. Mr. Shor, a construction business owner from Brooklyn, New York, who had given up his successful career in 1992 to search out a bone marrow donor, when he discovered that his 17-year old son had been diagnosed with leukaemia. His son unfortunately never received a bone marrow transplant and lost his fight with leukaemia. Steve has continued to dedicate his life to cancer research founding the National Children's Leukemia Foundation and working with scientists in hopes to find "The Cure."
"I always thought the cure for cancer had to come from core stem cells," Steve said. "We started from a very different point. We asked: what are the mechanisms that make cancer cells grow?"
First time trial left them sceptical bu
|SOURCE Frost & Sullivan|
Copyright©2010 PR Newswire.
All rights reserved